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The Bone Marrow and Liver Fibrosis: Friend or Foe?
See “Negligible contribution of bone marrow-
derived cells to collagen production during
hepatic fibrogenesis in mice,” by Higashiyama
R, Moro T, Nakao S, et al, on page 1459.
Bone marrow-derived cells circulate frequently throughthe liver and can engraft it. There is considerable
interest in the effects of these bone-marrow derived cells
on liver fibrosis and regeneration. It is important to
characterize these effects for 2 main reasons: to under-
stand the pathogenesis of liver fibrosis with the aim of
developing antifibrotic therapies, and because bone mar-
row-based cell therapy has been proposed as a clinical
tool to promote liver regeneration and inhibit liver fibro-
sis. It has been reported that various components of the
bone marrow can have antifibrotic effects on the liver.1
Animal studies have shown that the bone marrow-derived
scar-associated macrophage population can influence strongly
the fibrotic response to liver injury, promoting liver scar
production during injury and promoting scar resolution
after the cessation of injury.2 Bone marrow-derived en-
dothelial progenitor cells have been used in rodent mod-
els of fibrosis to reduce liver damage3 and bone marrow
progenitors have been used to repair hepatic sinusoidal
endothelium after liver injury.4 Bringing immediacy to
this matter is the fact that several groups are beginning
to perform clinical studies of autologous bone marrow
cell therapy for liver disease.5–8 Because the aim of such
bone marrow cell therapy is to reduce hepatic fibrosis and
promote liver regeneration, one would not want to inject
cells into the liver that could either directly make scar
tissue or indirectly promote endogenous scar production.
In this regard, there have been reports that bone marrow
cells or their progeny can circulate into various damaged
organs and differentiate into myofibroblasts or fibro-
cytes.9 Several studies have suggested that bone marrow
contributes to scar forming cells of various types in the
liver.10–18 In this month’s issue of GASTROENTEROLOGY,
however, Higashiyama et al19 report their findings that
the bone marrow contributes little to liver fibrosis or
myofibroblasts in a mouse bone marrow transplantation
model.
The bone marrow contains 2 main stem cell compart-
ments, namely hematopoietic stem cells (HSCs) and mes-
enchymal stem cells (MSCs) (Figure 1). Endothelial pro-
genitor cells can also be derived from bone marrow. HSCs
give rise to myeloid and lymphoid lineages, including
macrophages, and are known to be both radio- and
chemosensitive. Thus, after lethal irradiation and bone
marrow transplantation, HSCs in recipient animals are of
donor origin, which enables HSC transplantation-based
lineage tracing studies. MSCs are less well defined and
can give rise to bone, cartilage, and fat lineages, as well as
to fibroblast cells. MSCs have been shown to remain of
recipient origin after bone marrow transplantation be-
cause MSCs are radio- and chemoresistant.20,21 Therefore,
after lethal irradiation and bone marrow transplantation,
a chimeric bone marrow is created where HSCs are of
donor origin and MSCs are of recipient origin. Using
bone marrow transplantation as a mechanism of lineage
tracing, investigators can track transplantable bone mar-
row elements, that is, HSCs and their progeny.
Higashiyama et al19 used a model whereby whole bone
marrow from a constitutively green fluorescent protein
(GFP)-expressing donor was transplanted into irradiated
recipients. In the absence of details regarding the chimer-
ism achieved in the bone marrow mesenchymal compart-
ment, it is impossible to determine the relative propor-
tions of donor and recipient MSCs, and it may be that
the primary donor cell population studied was derived
from HSCs and consisted principally of inflammatory
and hematopoietic cells. Interestingly, the authors report
little evidence of collagen transcription in the liver from
these bone marrow-derived cells. This contradicts the
work of Kisseleva et al,15 in which bone marrow from
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collagen 1(I)-GFP reporter mice was transplanted into
wild-type recipients before bile duct ligation liver injury,
revealing a population of bone marrow-derived CD45
fibrocytes that were transcriptionally active for collagen.
Two previous studies have attempted to analyze the rel-
ative contribution of the hematopoietic and mesenchy-
mal compartments to the hepatic scar forming popula-
tion in the liver. Russo et al14 found that HSCs supplied
few, if any, myofibroblasts to the damaged liver and that
MSCs were a more likely source of liver myofibroblasts. Li
et al22 recently replicated these findings and took these
observations further. In an interesting paper, they sug-
gested that MSCs migrated to the liver from the bone
marrow along a sphingosine 1-phosphate (S1P) gradient.
By using suramin, a selective S1P3 receptor antagonist,
they showed potent inhibition of MSC migration to S1P
in vitro. Furthermore when the antagonist was adminis-
tered in vivo, fewer GFP-positive myofibroblasts en-
grafted the liver, implying that the drug had prevented
migration of these cells from the bone marrow to the
damaged liver. What requires further clarification is
whether in these studies the MSCs engrafted the liver
directly after injection, or whether this truly represented
pathophysiologic homing from the bone marrow. Fur-
ther experiments are thus required to give a full picture
of the role of the bone marrow in liver fibrosis.
Higashiyama et al19 found few bone marrow-derived
fibrotic cells in the livers of transplanted animals, al-
though they did observe a population of GFP-positive/
-smooth muscle antibody (SMA)-positive cells in recip-
ient livers (Figure 3). It would have been informative had
they provided a more extensive characterization of these
bone marrow-derived myofibroblasts. This could have
been performed in situ in the liver (using dual staining
for glial fibrillary acidic protein [GFAP], desmin, vimen-
tin, etc), or by isolating the GFP-positive cells and exam-
ining them in detail ex vivo. This second method was
carried out originally by Baba et al in 2004,10 who re-
ported isolating hepatic stellate cells from the livers of
mice that had received transplants of GFP-positive bone
marrow; a proportion of these stellate cells were found to
be strongly GFP positive. The findings of Higashiyama et
al19 contradict several recent studies that identified bone
marrow-derived fibrotic cells in the injured liver. In these
studies, a number of different techniques to trace cell
lineage were used, including bone marrow transplanta-
tion into wild-type mice from donors with constitutive
reporter gene expression, and gender mismatched bone
Figure 1. The potential interaction between the bone marrow (BM) and the liver either during liver injury or as a potential therapy.
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marrow transplantation with sex chromosome tracking
techniques. This allowed the detection of a range of bone
marrow-derived cells in the liver using a variety of mark-
ers (vimentin, -SMA, desmin, GFAP, collagen-1; Table
1). Some investigators have carefully isolated hepatic
stellate cells and found bone marrow markers (GFP and
sex chromosomes).10,14 Higashiyama et al19 suggest tissue
autofluorescence as a cause for the discrepancy between
their findings and those of other groups. Modern confo-
cal microscopy should allow this distinction to be made
and, interestingly, autofluorescence was considered by
Miyata et al, who performed anti-GFP immunostaining
to confirm the specificity of their eGFP tracking tech-
nique.16
It is important to know which cells are capable of
either secreting collagen in the liver or inducing collagen
secretion from endogenous cells. Indeed, MSCs can be
coaxed into a hepatocyte-like phenotype and have some
limited degree of hepatocytic function in vitro. For clin-
ical use, MSC-derived hepatocyte-like cells would need to
remain hepatocyte-like within the recipient liver, even in
the context of ongoing inflammation and injury; rever-
sion to a mesenchymal phenotype would be highly un-
desirable. Exogenously derived MSCs have been proposed
to enhance liver regeneration23 and reduce liver fibrosis
in some reports24; however, other reports have been less
positive. di Bonzo et al11 showed that exogenous MSCs
were much more likely to adopt a myofibroblast pheno-
type (-SMA positive) than a hepatocyte phenotype in
the chronically injured liver. Although there have been
several reports of the beneficial effect of MSCs on liver
fibrosis in rodent models, other studies have found no
benefit.25 Time will tell whether this potentially promis-
ing therapy can be translated into the clinic. Factors that
need to be considered include whether the MSCs them-
selves produce scar or matrix-degrading substances, and
whether they have a net positive or negative effect on the
surrounding cell population. If MSCs are found to be
beneficial, it will be important to know how they compare
with other putative therapeutic bone marrow-derived cells
such as CD34 cells and monocytes.
The virtual absence of collagen production from bone
marrow-derived cells, probably primarily HSCs, in the
injured liver observed by Higashiyama et al19 encourages
the further testing of autologous HSCs (such as CD34
and CD133 cells and derivatives such as monocytes) for
liver therapy. To date, small, uncontrolled studies have
suggested an overall benefit.5–7 There are obviously 2
main ways to address this particular issue—larger, ran-
domized clinical studies or additional mechanistic stud-
ies in rodent and other model systems to define the
optimal cells for therapy. At this stage, it seems reason-
able that both approaches be undertaken with care. Ta
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